YC S21
Promakhos Therapeutics
A therapeutics platform for curing inflammatory disorders
About
We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.
Founders
- Katerina Chatzi
- Jasper Edgar Neggers
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Promakhos Therapeutics.
See family office activityIndustry & Focus
HealthcareTherapeutics